impaired, Fertility

117-81-7

BJQHLKABXJIVAM-UHFFFAOYNA-N

BJQHLKABXJIVAM-UHFFFAOYSA-N

Di(2-ethylhexyl) phthalate

1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester DEHP 1,2-Benzedicarboxylic acid, bis(2-ethyl-hexyl) ester 1,2-Benzenedicarboxylic acid bis(2-ethylhexyl) ester 1,2-Benzenedicarboxylic acid, 1,2-bis(2-ethylhexyl) ester 1,2-Benzenedicarboxylic acid,bis(2-ethylhexylester) Bis(2-ethylhexyl) 1,2-benzenedicarboxylate Bis(2-ethylhexyl) o-phthalate bis(2-ethylhexyl) phthalate Bis(2-ethylhexyl)phthalat Bis(2-ethylhexyl)phthalate Bisoflex 81 Bisoflex DOP Corflex 400 Di(2-ethylhexyl)phthalate Di(isooctyl) phthalate Di-2-ethylhexlphthalate Di-2-ethylhexyl phthalate DI-2-ETHYLHEXYL-PHTHALATE Diacizer DOP Diethylhexyl phthalate Dioctylphthalate DOF Ergoplast FDO Ergoplast FDO-S ETHYLHEXYL PHTHALATE Eviplast 80 Eviplast 81 Fleximel Flexol DOD Flexol DOP ftlalato de bis(2-etilhexilo) Garbeflex DOP-D 40 Good-rite GP 264 Hatco DOP Jayflex DOP Kodaflex DEHP Kodaflex DOP Monocizer DOP NSC 17069 Palatinol AH Palatinol AH-L Phtalate de Bis (Ethyle-2-Hexyle) Phtalate de bis(2-ethylhexyle) PHTHALATE, BIS(2-ETHYLHEXYL) Phthalic acid di(2-ethylhexyl) ester Phthalic acid, bis(2-ethylhexyl) ester PHTHALIC ACID, BIS(2-ETHYLHEXYL)ESTER PHTHALSAEURE-BIS-(2-AETHYLHEXYL)-ESTER Pittsburgh PX 138 Plasthall DOP Reomol D 79P Sansocizer DOP Sansocizer R 8000 Sconamoll DOP Staflex DOP Truflex DOP Vestinol AH Vinycizer 80 Vinycizer 80K Witcizer 312

DTXSID5020607

637-07-0

KNHUKKLJHYUCFP-UHFFFAOYSA-N

Clofibrate

ethyl-p-chlorophenoxyisobutyrate Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester 2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester Abitrate Amotril Anparton Arteriosan Artevil Ateculon Ateriosan Atheropront Atromid S Atromidin Azionyl Bioscleran Cartagyl Claripex Claripex CPIB Clobren SF Clofibrat clofibrato Clofinit Ethyl (p-chlorophenoxy) isobutyrate Ethyl 2-(4-chlorophenoxy)-2-methylpropionate Ethyl 2-(4-chlorophenoxy)isobutyrate Ethyl 2-(p-chlorophenoxy)-2-methylpropionate Ethyl 2-(p-chlorophenoxy)isobutyrate Ethyl clofibrate Ethyl p-chlorophenoxyisobutyrate Ethyl α-(4-chlorophenoxy)isobutyrate Ethyl α-(4-chlorophenoxy)-α-methylpropionate Ethyl α-(p-chlorophenoxy)isobutyrate Ethyl α-(p-chlorophenoxy)-α-methylpropionate Hyclorate Lipavil Lipavlon Lipomid Liprinal Miscleron Misclerone Neo-Atromid Normolipol NSC 79389 p-Chlorophenoxyisobutyric acid ethyl ester Propionic acid, 2-(p-chlorophenoxy)-2-methyl-, ethyl ester Recolip Regelan Serotinex Sklerepmexe Sklerolip Skleromexe Sklero-Tablinene Ticlobran Xyduril

DTXSID3020336

3771-19-5

XJGBDJOMWKAZJS-UHFFFAOYNA-N

XJGBDJOMWKAZJS-UHFFFAOYSA-N

Nafenopin

DTXSID8020911

52214-84-3

KPSRODZRAIWAKH-UHFFFAOYNA-N

KPSRODZRAIWAKH-UHFFFAOYSA-N

Ciprofibrate

DTXSID8020331

25812-30-0

HEMJJKBWTPKOJG-UHFFFAOYSA-N

Gemfibrozil

Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid Decrelip gemfibrozilo Gevilon Lopizid Trialmin 900 Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-

DTXSID0020652

41859-67-0

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Bezafibrate

Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- Befizal Benzofibrate Bezafibrat bezafibrato Bezalip Bezatol Difaterol

DTXSID3029869

49562-28-9

YMTINGFKWWXKFG-UHFFFAOYSA-N

Fenofibrate

Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester Ankebin Clorofibrate Elasterin Fenobrate Fenofibrat fenofibrato Fenogal Fenotard Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate Lipanthyl Lipantil Lipicard Lipidil Lipidil Supra Lipirex Lipoclar Lipofene Liposit MeltDose Nolipax NSC 281319 Procetofen Procetofene Procetoken Protolipan Secalip

DTXSID2029874

79902-63-9

RYMZZMVNJRMUDD-HGQWONQESA-N

Simvastatin

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester (+)-Simvastatin Apo-Simvastatin Bestatin 20 Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1α,3α,7β,8β(2S*,4S*),8aβ]]- Cholestat Co-Simvastatin Kolestevan L 644128-000U Lipinorm Liponorm Lipovas Lodales Modutrol Nor-Vastina Novo-Simvastatin Pms-simvastatin Simastin 20 Simovil Simvastatin lactone Simvotin Sinvacor Sinvascor Sivastin Starstat 20 Synvinolin Valemia Velostatin

DTXSID0023581

CHEBI:81568

CHEBI Luteinizing hormone

PR:000013056

PR peroxisome proliferator-activated receptor alpha

CHEBI:17347

CHEBI testosterone

CHEBI:16113

CHEBI cholesterol

D005298

MESH fertility

GO:0042446

GO hormone biosynthetic process

D006965

MESH hyperplasia

GO:0008283

GO cell proliferation

GO:0035357

GO peroxisome proliferator activated receptor signaling pathway

GO:0061370

GO testosterone biosynthetic process

GO:0006839

GO mitochondrial transport

WIKI decreased

WIKI increased

Di(2-ethylhexyl) phthalate

2016-11-29T18:42:26

Mono(2-ethylhexyl) phthalate

2016-11-29T18:42:26

Stressor:205 pirinixic acid (WY-14,643)

2020-12-19T09:06:20

Clofibrate

2016-11-29T18:42:27

Nafenopin

2016-11-29T18:42:27

ciprofibrate

2016-11-29T18:42:27

Gemfibrozil Fibrate drug

2016-11-29T18:42:27

2020-03-31T10:24:40

PERFLUOROOCTANOIC ACID

2016-11-29T18:42:27

Bezafibrate

2016-11-29T18:42:27

Fenofibrate

2016-11-29T18:42:27

Simvastatin

2020-05-06T09:41:35

10116

NCBI rat

10090

NCBI mouse

WCS_9606

common toxicological species human

10095

NCBI mice

impaired, Fertility

Individual

Biological state capability to produce offspring Biological compartments System General role in biology Fertility is the capacity to conceive or induce conception. Impairment of fertility represents disorders of male or female reproductive functions or capacity.

As a measure, fertility rate, is the number of offspring born per mating pair, individual or population.

High

Adult, reproductively mature

High High High

AOPWiki 2016-11-29T18:41:24

2016-12-02T09:21:49

Increase, Luteinizing hormone (LH)

Cellular

CL:0000178

CL Leydig cell

AOPWiki 2016-11-29T18:41:24

2017-09-16T10:15:08

Hyperplasia, Leydig cell

Cellular

CL:0000178

CL Leydig cell

AOPWiki 2016-11-29T18:41:24

2017-09-27T14:00:47

Increase proliferation, Leydig cell

Cellular

CL:0000178

CL Leydig cell

AOPWiki 2016-11-29T18:41:24

2017-09-16T10:15:08

Activation, PPARα

Molecular

Gene expression occurs in a coordinated fashion (Judson et al., 2012). The many observations of altered gene expression following binding of ligand to PPARα led to systematic investigations of the genomic signature that corresponds to PPARα activation (Tamura et al., 2006; Kupershmidt et al., 2010; Rosen et al., 2017; Rooney et al., 2018; Corton et al., 2020; Hill et al., 2020; Lewis et al., 2020). Specific gene with increased expression following PPARα activation include Cyp4a1, Cpt1B, and Lpl. More generally, the pathways activated include: <ul> <li>Genes involved in Metabolism of lipids and lipoproteins</li> <li>Fatty acid metabolism</li> <li>Genes involved in Fatty acid, triacylglycerol, and ketone body metabolism</li> <li>PPAR signaling pathway</li> <li>Peroxisome</li> <li>Genes involved in Cell Cycle</li> </ul> Biological state The Peroxisome Proliferator Activated receptor α (PPARα) belongs to the <a href="/wiki/index.php/Peroxisome_Proliferator_Activated_receptors_(PPARs;_NR1C)" title="Peroxisome Proliferator Activated receptors (PPARs; NR1C)">Peroxisome Proliferator Activated receptors (PPARs; NR1C)</a> steroid/thyroid/retinoid receptor superfamily of transcription factors. Biological compartments PPARα is expressed in high levels in tissues that perform significant catabolism of fatty acids (FAs), such as brown adipose tissue, liver, heart, kidney, and intestine (Michalik et al. 2006). The receptor is present also in skeletal muscle, intestine, pancreas, lung, placenta and testes (Mukherjee et al. 1997), (Schultz et al. 1999). General role in biology PPARs are activated by fatty acids and their derivatives; they are sensors of dietary lipids and are involved in lipid and carbohydrate metabolism, immune response and peroxisome proliferation (Wahli and Desvergne 1999), (Evans, Barish, & Wang, 2004). PAPRα is a also a target of hypothalamic hormone signalling and was found to play a role in embryonic development (Yessoufou and Wahli 2010). Fibrates, activators of PPARα, are commonly used to treat hypertriglyceridemia and other dyslipidemic states as they have been shown to decrease circulating lipid levels (Lefebvre et al. 2006).

Binding of ligands to PPARα is measured using binding assays in vitro and in silico, whereas the information about functional activation is derived from transactivation assays (e.g. transactivation assay with reporter gene) that demonstrate functional activation of a nuclear receptor by a specific compound. Binding of agonists within the ligand-binding site of PPARs causes a conformational change of nuclear receptor that promotes binding to transcriptional co-activators. Conversely, binding of antagonists results in a conformation that favours the binding of co-repressors (Yu and Reddy 2007), (Viswakarma et al. 2010). Transactivation assays are performed using transient or stably transfected cells with the PPARα expression plasmid and a reporter plasmid, respectively. There are also other methods that have been used to measure PPARα activity, such as the Electrophoretic Mobility Shift Assay (EMSA) or commercially available PPARα transcription factor assay kits, see Table 1. The transactivation (stable transfection) assay provides the most applicable OECD Level 2 assay (i.e. In vitro assays providing mechanistic data) aimed at identifying the initiating event leading to an adverse outcome (LeBlanc, Norris, and Kloas 2011). A recent study characterized the PPARα ligand binding domain for the purpose of next-generation metabolic disease drugs (Kamata et al. 2020). The most direct measure of this MIE is microarray profiling from large gene expression databases TG-GATEs and DrugMatrix coupled with t statistical analysis of whole genome expression profiles (Svoboda et al., 2019; Igarashi et al., 2015) From these data, A gene expression signature of 131 PPARα-dependent genes was built using microarray profiles from the livers of wild-type and PPARα-null mice. A quantitative measure of this expression signature is a measure of similarity/correlation between the PPARα signature and positive and negative test sets is provided by the Running Fisher test (Corton et al., 2020; Hill et al., 2020; Kupershmidt et al., 2010; Lewis et al., 2020; Rooney et al., 2018). A gene expression signature of 131 PPARα-dependent genes was built using microarray profiles from the livers of wild-type and PPARα-null mice. A quantitative measure of this expression signature would be a measure of similarity/correlation between the PPARα signature and positive and negative test sets is provided by the Running Fisher test (Kupershmidt et al., 2010; Rooney et al., 2018; Corton et al., 2020). For all substances, MIE activation does not rise monotonically over dose or time. These fluctuations are likely due to variations in cofactor availability or access to the site of transcription (Gaillard et al., 2006; Koppen et al., 2009; Kupershmidt et al., 2010; Ong et al., 2010; Chow et al., 2011; De Vos et al., 2011; Simon et al., 2015). . <table align="left" border="1" cellpadding="1" cellspacing="1" style="height:3px; width:100px"> <caption>Measurements of PPARα Activation</caption> <thead> <tr> <th scope="row">Method/Test</th> <th scope="col">Test Principle</th> <th scope="col">Test Environment</th> <th scope="col">Test Outcome</th> <th scope="col">Assay Type/Domain</th> </tr> </thead> <tbody> <tr> <th scope="row"> molecular modelling; docking simulation </th> <td>Computational simulation of  ligand binding </td> <td>In silico</td> <td>Prediction off binding interaction </td> <td>Quantitative virtual screeings</td> </tr> <tr> <th scope="row">Scintillation proximity binding assay</th> <td>Direct binding of ligand</td> <td>In vitro</td> <td>Identifies compouds that bind to PPARα</td> <td>Qualitative in vitro screening</td> </tr> <tr> <th scope="row">PPARα reporter gene assay</th> <td>Quantify changes in in PPARα activation via a sensitive surrogate </td> <td>In vitro, Ex vivo</td> <td>Measures changes in activity of genes linked to a PPARα receptor element</td> <td>Quantitative in vitro screening</td> </tr> <tr> <th scope="row">Electrophoretic Band Shift</th> <td>determines if a protein or protein mixture will bind to a specific DNA or RNA sequence</td> <td>In vitro</td> <td>Measures cofactor binding by changes in gel mobility</td> <td>Quantitative in vitro screening</td> </tr> <tr> <th scope="row">Microarray profiling</th> <td>Develop MIE-specific sets of gene expression biomarkers</td> <td>In vivo</td> <td>Classification of PPARα biomarker genes with statistical methods</td> <td>Quantitative in vivo screening</td> </tr> </tbody> </table>

PPARα has been identified in frog (Xenopus laevis), mouse, human, rat, fish, hamster and chicken (reviewed in (Wahli and Desvergne 1999)).

UBERON:0002107

UBERON liver

CL:0000255

CL eukaryotic cell

High High High

Bhattacharya, Nandini, Jannette M Dufour, My-Nuong Vo, Janice Okita, Richard Okita, and Kwan Hee Kim. 2005. “Differential Effects of Phthalates on the Testis and the Liver.” Biology of Reproduction 72 (3) (March): 745–54. doi:10.1095/biolreprod.104.031583. Bility, Moses T, Jerry T Thompson, Richard H McKee, Raymond M David, John H Butala, John P Vanden Heuvel, and Jeffrey M Peters. 2004. “Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (PPARs) by Phthalate Monoesters.” Toxicological Sciences : An Official Journal of the Society of Toxicology 82 (1) (November): 170–82. doi:10.1093/toxsci/kfh253. Chow, C. C., Ong, K. M., Dougherty, E. J., & Simons, S. S. (2011). Inferring mechanisms from dose-response curves. Methods Enzymol, 487, 465-483. https://doi.org/10.1016/B978-0-12-381270-4.00016-0 Corton, J. C., Hill, T., Sutherland, J. J., Stevens, J. L., & Rooney, J. (2020). A Set of Six Gene Expression Biomarkers Identify Rat Liver Tumorigens in Short-Term Assays. Toxicol Sci. https://doi.org/10.1093/toxsci/kfaa101 De Vos, D., Bruggeman, F. J., Westerhoff, H. V., & Bakker, B. M. (2011). How molecular competition influences fluxes in gene expression networks. PLoS One, 6(12), e28494. https://doi.org/10.1371/journal.pone.0028494 Dufour, Jannette M, My-Nuong Vo, Nandini Bhattacharya, Janice Okita, Richard Okita, and Kwan Hee Kim. 2003. “Peroxisome Proliferators Disrupt Retinoic Acid Receptor Alpha Signaling in the Testis.” Biology of Reproduction 68 (4) (April): 1215–24. doi:10.1095/biolreprod.102.010488. Feige, Jérôme N, Laurent Gelman, Daniel Rossi, Vincent Zoete, Raphaël Métivier, Cicerone Tudor, Silvia I Anghel, et al. 2007. “The Endocrine Disruptor Monoethyl-Hexyl-Phthalate Is a Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator That Promotes Adipogenesis.” The Journal of Biological Chemistry 282 (26) (June 29): 19152–66. doi:10.1074/jbc.M702724200. Gaillard, S., Grasfeder, L. L., Haeffele, C. L., Lobenhofer, E. K., Chu, T.-M., Wolfinger, R., Kazmin, D., Koves, T. R., Muoio, D. M., Chang, C.-y., & McDonnell, D. P. (2006). Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. Mol Cell, 24(5), 797-803. https://doi.org/10.1016/j.molcel.2006.10.012 Hill, T., Rooney, J., Abedini, J., El-Masri, H., Wood, C. E., & Corton, J. C. (2020). Gene Expression Thresholds Derived From Short-Term Exposures Identify Rat Liver Tumorigens. Toxicol Sci. https://doi.org/10.1093/toxsci/kfaa102 Hurst, Christopher H, and David J Waxman. 2003. “Activation of PPARalpha and PPARgamma by Environmental Phthalate Monoesters.” Toxicological Sciences : An Official Journal of the Society of Toxicology 74 (2) (August): 297–308. doi:10.1093/toxsci/kfg145. Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., & Yamada, H. (2015). Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res, 43(Database issue), D921-7. https://doi.org/10.1093/nar/gku955 Kamata S, Oyama T, Saito K, Honda A, Yamamoto Y, Suda K, Ishikawa R, Itoh T, Watanabe Y, Shibata T, Uchida K, Suematsu M, Ishii I. PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates. iScience. 2020;23(11):101727. 10.1016/j.isci.2020.101727 Kaya, Taner, Scott C Mohr, David J Waxman, and Sandor Vajda. 2006. “Computational Screening of Phthalate Monoesters for Binding to PPARgamma.” Chemical Research in Toxicology 19 (8) (August): 999–1009. doi:10.1021/tx050301s. Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E. H., Ruijtenbeek, R., & Kalkhoven, E. (2009). Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor. Mol Cell Proteomics, 8(10), 2212-2226. https://doi.org/10.1074/mcp.M900209-MCP200 Kupershmidt, I., Su, Q. J., Grewal, A., Sundaresh, S., Halperin, I., Flynn, J., Shekar, M., Wang, H., Park, J., Cui, W., Wall, G. D., Wisotzkey, R., Alag, S., Akhtari, S., & Ronaghi, M. (2010). Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One, 5(9). https://doi.org/10.1371/journal.pone.0013066 Lampen, Alfonso, Susan Zimnik, and Heinz Nau. 2003. “Teratogenic Phthalate Esters and Metabolites Activate the Nuclear Receptors PPARs and Induce Differentiation of F9 Cells.” Toxicology and Applied Pharmacology 188 (1) (April): 14–23. doi:10.1016/S0041-008X(03)00014-0. Lapinskas, Paula J., Sherri Brown, Lisa M. Leesnitzer, Steven Blanchard, Cyndi Swanson, Russell C. Cattley, and J. Christopher Corton. 2005. “Role of PPARα in Mediating the Effects of Phthalates and Metabolites in the Liver.” Toxicology 207 (1): 149–163. Le Maire, Albane, Marina Grimaldi, Dominique Roecklin, Sonia Dagnino, Valérie Vivat-Hannah, Patrick Balaguer, and William Bourguet. 2009. “Activation of RXR-PPAR Heterodimers by Organotin Environmental Endocrine Disruptors.” EMBO Reports 10 (4) (April): 367–73. doi:10.1038/embor.2009.8. LeBlanc, GA, DO Norris, and W Kloas. 2011. “Detailed Review Paper State of the Science on Novel In Vitro and In Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors” (178). Lefebvre, Philippe, Giulia Chinetti, Jean-Charles Fruchart, and Bart Staels. 2006. “Sorting out the Roles of PPAR Alpha in Energy Metabolism and Vascular Homeostasis.” The Journal of Clinical Investigation 116 (3) (March): 571–80. doi:10.1172/JCI27989. Lewis, R. W., Hill, T., & Corton, J. C. (2020). A set of six Gene expression biomarkers and their thresholds identify rat liver tumorigens in short-term assays. Toxicology, 443, 152547. https://doi.org/10.1016/j.tox.2020.152547 Maloney, Erin K., and David J. Waxman. 1999. “Trans-Activation of PPARα and PPARγ by Structurally Diverse Environmental Chemicals.” Toxicology and Applied Pharmacology 161 (2): 209–218. Michalik, Liliane, Johan Auwerx, Joel P Berger, V Krishna Chatterjee, Christopher K Glass, Frank J Gonzalez, Paul A Grimaldi, et al. 2006. “International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors.” Pharmacological Reviews 58 (4) (December): 726–41. doi:10.1124/pr.58.4.5. Mukherjee, R, L Jow, G E Croston, and J R Paterniti. 1997. “Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-Activated Receptor (PPAR) Isoforms PPARgamma2 versus PPARgamma1 and Activation with Retinoid X Receptor Agonists and Antagonists.” The Journal of Biological Chemistry 272 (12) (March 21): 8071–6. Ong, K. M., Blackford, J. A., Kagan, B. L., Simons, S. S., & Chow, C. C. (2010). A theoretical framework for gene induction and experimental comparisons. Proc Natl Acad Sci U S A, 107(15), 7107-7112. https://doi.org/10.1073/pnas.0911095107 Rooney, J., Hill, T., Qin, C., Sistare, F. D., & Corton, J. C. (2018). Adverse outcome pathway-driven identification of rat liver tumorigens in short-term assays. Toxicol Appl Pharmacol, 356, 99-113. https://doi.org/10.1016/j.taap.2018.07.023 Schultz, R, W Yan, J Toppari, A Völkl, J A Gustafsson, and M Pelto-Huikko. 1999. “Expression of Peroxisome Proliferator-Activated Receptor Alpha Messenger Ribonucleic Acid and Protein in Human and Rat Testis.” Endocrinology 140 (7) (July): 2968–75. doi:10.1210/endo.140.7.6858. Simon, T. W., Budinsky, R. A., & Rowlands, J. C. (2015). A model for aryl hydrocarbon receptor-activated gene expression shows potency and efficacy changes and predicts squelching due to competition for transcription co-activators. PLoS One, 10(6), e0127952. https://doi.org/10.1371/journal.pone.0127952. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart. 1998. “Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism.” Circulation 98 (19) (November 10): 2088–2093. doi:10.1161/01.CIR.98.19.2088. Svoboda, D. L., Saddler, T., & Auerbach, S. S. (2019). An Overview of National Toxicology Program’s Toxicogenomic Applications: DrugMatrix and ToxFX.  In Advances in Computational Toxicology (pp. 141-157). Springer. https://link.springer.com/chapter/10.1007/978-3-030-16443-0_8 ToxCastTM Data. “ToxCastTM Data.” US Environmental Protection Agency. <a class="external free" href="http://www.epa.gov/ncct/toxcast/data.html" rel="nofollow" target="_blank">http://www.epa.gov/ncct/toxcast/data.html</a> Vanden Heuvel, John P, Jerry T Thompson, Steven R Frame, and Peter J Gillies. 2006. “Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-Alpha, -Beta, and -Gamma, Liver X Receptor-Beta, and Retinoid X Rec.” Toxicological Sciences : An Official Journal of the Society of Toxicology 92 (2) (August): 476–89. doi:10.1093/toxsci/kfl014. Venkata, Nagaraj Gopisetty, Jodie a Robinson, Peter J Cabot, Barbara Davis, Greg R Monteith, and Sarah J Roberts-Thomson. 2006. “Mono(2-Ethylhexyl)phthalate and Mono-N-Butyl Phthalate Activation of Peroxisome Proliferator Activated-Receptors Alpha and Gamma in Breast.” Toxicology Letters 163 (3) (June 1): 224–34. doi:10.1016/j.toxlet.2005.11.001. Viswakarma, Navin, Yuzhi Jia, Liang Bai, Aurore Vluggens, Jayme Borensztajn, Jianming Xu, and Janardan K Reddy. 2010. “Coactivators in PPAR-Regulated Gene Expression.” PPAR Research 2010 (January). doi:10.1155/2010/250126. Wahli, Walter, and B Desvergne. 1999. “Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism.” Endocrine Reviews 20 (5) (October): 649–88. Wu, Bin, Jie Gao, and Ming-wei Wang. 2005. “Development of a Complex Scintillation Proximity Assay for High-Throughput Screening of PPARgamma Modulators.” Acta Pharmacologica Sinica 26 (3) (March): 339–44. doi:10.1111/j.1745-7254.2005.00040.x. Xu, Chuan, Ji-An Chen, Zhiqun Qiu, Qing Zhao, Jiaohua Luo, Lan Yang, Hui Zeng, et al. 2010. “Ovotoxicity and PPAR-Mediated Aromatase Downregulation in Female Sprague-Dawley Rats Following Combined Oral Exposure to Benzo[a]pyrene and Di-(2-Ethylhexyl) Phthalate.” Toxicology Letters 199 (3) (December 15): 323–32. doi:10.1016/j.toxlet.2010.09.015. Yessoufou, a, and W Wahli. 2010. “Multifaceted Roles of Peroxisome Proliferator-Activated Receptors (PPARs) at the Cellular and Whole Organism Levels.” Swiss Medical Weekly 140 (September) (January): w13071. doi:10.4414/smw.2010.13071. Yu, Songtao, and Janardan K Reddy. 2007. “Transcription Coactivators for Peroxisome Proliferator-Activated Receptors.” Biochimica et Biophysica Acta 1771 (8) (August): 936–51. doi:10.1016/j.bbalip.2007.01.008. AOPWiki 2016-11-29T18:41:23

2020-12-28T12:48:16

Reduction, fetal/adult testosterone

Reduction of testosterone

Tissue

Biological state Testosterone (T) is a steroid hormone from the androgen group. T serves as a substrate for two metabolic pathways that produce antagonistic sex steroids. Biological compartments Testosterone is synthesized by the gonads and other steroidogenic tissues (e.g., brain, adipose), acts locally and/or is transported to other tissues via blood circulation. Leydig cells are the testosterone-producing cells of the testis. General role in biology Androgens, the main male sex steroids, are the critical factors responsible for the development of the male phenotype during embryogenesis and for the achievement of sexual maturation at puberty. In adulthood, androgens remain essential for the maintenance of male reproductive function and behaviour. Apart from their effects on reproduction, androgens affect a wide variety of non-reproductive tissues such as skin, bone, muscle, and brain (Heemers, Verhoeven, & Swinnen, 2006). Androgens, principally T and 5α-dihydrotestosterone (DHT), exert most of their effects by interacting with a specific receptor, the androgen receptor (AR), for review see (Murashima, Kishigami, Thomson, & Yamada, 2015). On the one hand, testosterone can be reduced by 5α-reductase to produce 5α dihydrotestosterone (DHT). On the other hand, testosterone can be aromatized to generate estrogens. Testosterone effects can also be classified by the age of usual occurrence, postnatal effects in both males and females are mostly dependent on the levels and duration of circulating free testosterone.

Testosterone can be measured by immunoassays and by isotope-dilution gas chromatography-mass spectrometry in serum (Taieb et al., 2003), (Paduch et al., 2014). Testosterone levels are measured i.a. in: Fish Lifecycle Toxicity Test (FLCTT) (US EPA OPPTS 850.1500), Male pubertal assay (PP Male Assay) (US EPA OPPTS 890.1500), OECD TG 441: Hershberger Bioassay in Rats (H Assay).

Key enzymes needed for testosterone production first appear in the common ancestor of amphioxus and vertebrates (Baker 2011). Consequently, this key event is applicable to most vertebrates, including humans.

UBERON:0000178

UBERON blood

High High High

Heemers, H. V, Verhoeven, G., & Swinnen, J. V. (2006). Androgen activation of the sterol regulatory element-binding protein pathway: Current insights. Molecular Endocrinology (Baltimore, Md.), 20(10), 2265–77. doi:10.1210/me.2005-0479 Murashima, A., Kishigami, S., Thomson, A., & Yamada, G. (2015). Androgens and mammalian male reproductive tract development. Biochimica et Biophysica Acta, 1849(2), 163–170. doi:10.1016/j.bbagrm.2014.05.020 Paduch, D. A., Brannigan, R. E., Fuchs, E. F., Kim, E. D., Marmar, J. L., & Sandlow, J. I. (2014). The laboratory diagnosis of testosterone deficiency. Urology, 83(5), 980–8. doi:10.1016/j.urology.2013.12.024 Taieb, J., Mathian, B., Millot, F., Patricot, M.-C., Mathieu, E., Queyrel, N., … Boudou, P. (2003). Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clinical Chemistry, 49(8), 1381–95. AOPWiki 2016-11-29T18:41:24

2023-05-17T08:53:46

Reduction, Testosterone synthesis in Leydig cells

Cellular

Biological state Testosterone is a steroid hormone from the androgen group and is found in humans and other vertebrates. Biological compartments In humans and other mammals, testosterone is secreted primarily by the testicles of males and, to a lesser extent, the ovaries of females and other steroidogenic tissues (e.g., brain, adipose). It either acts locally /or is transported to other tissues via blood circulation. Testosterone synthesis takes place within the mitochondria of Leydig cells, the testosterone-producing cells of the testis. It is produced upon stimulation of these cells by Luteinizing hormone (LH) that is secreted in pulses into the peripheral circulation by the pituitary gland in response to Gonadotropin-releasing hormone (GnRH) from the hypothalamus. Testosterone and its aromatized product, estradiol, feed back to the hypothalamus and pituitary gland to suppress transiently LH and thus testosterone production. In response to reduced testosterone levels, GnRH and LH are produced. This negative feedback cycle results in pulsatile secretion of LH followed by pulsatile production of testosterone (Ellis, Desjardins, and Fraser 1983), (Chandrashekar and Bartke 1998). General role in biology Testosterone is the principal male sex hormone and an anabolic steroid. Male sexual differentiation depends on testosterone (T), dihydrotestosterone (DHT), and the expression of androgen receptors by target cells (Manson and Carr 2003). During the development secretion of androgens by Leydig cells is essential for masculinization of the foetus (Nef 2000). The foetal Leydig cells develop in utero. These cells become competent to produce testosterone in rat by gestational day (GD) 15.5, with increasing production thereafter. Peak steroidogenic activity is reached just prior to birth, on GD19 (Chen, Ge, and Zirkin 2009). Testosterone secreted by foetal Leydig cells is required for the differentiation of the male urogenital system late in gestation (Huhtaniemi and Pelliniemi 1992). Foetal Leydig cells also play a role in the scrotal descent of the testis through their synthesis of insulin-like growth factor 3 (Insl3), for review see (Nef 2000). In humans, the first morphological sign of testicular differentiation is the formation of testicular cords, which can be seen between 6 and 7 weeks of gestation. Steroid-secreting Leydig cells can be seen in the testis at 8 weeks of gestation. At this period, the concentration of androgens in the testicular tissue and blood starts to rise, peaking at 14-16 weeks of gestation. This increase comes with an increase in the number of Leydig cells for review see (Rouiller-Fabre et al. 2009). Adult Leydig cells, which are distinct from the foetal Leydig cells, form during puberty and supply the testosterone required for the onset of spermatogenesis, among other functions. Distinct stages of adult Leydig cell development have been identified and characterized. The stem Leydig cells are undifferentiated cells that are capable of indefinite self-renewal but also of differentiation to steroidogenic cells. These cells give rise to progenitor Leydig cells, which proliferate, continue to differentiate, and give rise to the immature Leydig cells. Immature Leydig cells synthesize high levels of testosterone metabolites and develop into terminally differentiated adult Leydig cells, which produce high levels of testosterone. With aging, both serum and testicular testosterone concentrations progressively decline, for review see (Nef 2000). Androgens play a crucial role in the development and maintenance of male reproductive and sexual functions. Low levels of circulating androgens can cause disturbances in male sexual development, resulting in congenital abnormalities of the male reproductive tract. Later in life, this may cause reduced fertility, sexual dysfunction, decreased muscle formation and bone mineralisation, disturbances of fat metabolism, and cognitive dysfunction. Testosterone levels decrease as a process of ageing: signs and symptoms caused by this decline can be considered a normal part of ageing.

OECD TG 456 <a rel="nofollow" target="_blank" class="external autonumber" href="http://www.oecd-ilibrary.org/environment/test-no-456-h295r-steroidogenesis-assay_9789264122642-en">[1]</a> is the validated test guideline for an in vitro screen for chemical effects on steroidogenesis, specifically the production of 17ß-estradiol (E2) and testosterone (T). The testosterone syntheis can be measured in vitro cultured Leydig cells. The methods for culturing Leydig cells can be found in the Database Service on Alternative Methods to animal experimentation (DB-ALM): Leydig Cell-enriched Cultures <a rel="nofollow" target="_blank" class="external autonumber" href="http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_met=232">[2]</a>, Testicular Organ and Tissue Culture Systems <a rel="nofollow" target="_blank" class="external autonumber" href="http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_met=515">[3]</a>. Testosterone synthesis in vitro cultured cells can be measured indirectly by testosterone radioimmunoassay or analytical methods such as LC-MS.

CL:0000177

CL testosterone secreting cell

High High Low

Chandrashekar, V, and A Bartke. 1998. “The Role of Growth Hormone in the Control of Gonadotropin Secretion in Adult Male Rats.” Endocrinology 139 (3) (March): 1067–74. doi:10.1210/endo.139.3.5816. Ellis, G B, C Desjardins, and H M Fraser. 1983. “Control of Pulsatile LH Release in Male Rats.” Neuroendocrinology 37 (3) (September): 177–83. Huhtaniemi, I, and L J Pelliniemi. 1992. “Fetal Leydig Cells: Cellular Origin, Morphology, Life Span, and Special Functional Features.” Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 201 (2) (November): 125–40. Manson, Jeanne M, and Michael C Carr. 2003. “Molecular Epidemiology of Hypospadias: Review of Genetic and Environmental Risk Factors.” Birth Defects Research. Part A, Clinical and Molecular Teratology 67 (10) (October): 825–36. doi:10.1002/bdra.10084. Nef, S. 2000. “Hormones in Male Sexual Development.” Genes & Development 14 (24) (December 15): 3075–3086. doi:10.1101/gad.843800. Rouiller-Fabre, Virginie, Vincent Muczynski, Romain Lambrot, Charlotte Lécureuil, Hervé Coffigny, Catherine Pairault, Delphine Moison, et al. 2009. “Ontogenesis of Testicular Function in Humans.” Folia Histochemica et Cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 47 (5) (January): S19–24. doi:10.2478/v10042-009-0065-4. AOPWiki 2016-11-29T18:41:24

2017-09-16T10:14:33

Reduction, Cholesterol transport in mitochondria

Cellular

Biological state Steroidogenesis begins with the transport of cholesterol from intracellular stores into mitochondria. This process involves a series of protein-protein interactions involving cytosolic and mitochondrial proteins located at both the outer and inner mitochondrial membranes. In steroidogenic cells the cholesterol import to the mitochondrial inner membrane is crucial for steroid synthesis (Rone, Fan, and Papadopoulos 2009). This process is facilitated by the Scavenger Receptor Class B, type 1 (SR-B1) [more relevant for rodents, than for humans] that mediates the selective uptake of cholesterol esters from high-density lipoproteins. Steroidogenic acute regulatory protein (STAR) and the translator protein (TSPO) [former peripheral benzodiazepine receptor (PBR)] mediate cholesterol transport from the outer to the inner mitochondrial membrane. The conversion of cholesterol to pregnenolone is done by Cholesterol side-chain cleavage enzyme (P450scc), the start of steroidogenesis [reviewed in (Miller and Auchus 2011)]. Biological compartments In mitochondria of steroidogenic tissues there are two specialized mechanisms related to hormone synthesis: one by which cholesterol is delivered to the mitochondria and the other by which specialized intra-mitochondrial enzymes participate in the synthesis of hormonal steroids. General role in biology Systemic steroid hormones are primarily formed by the gonads, adrenal glands, and during in utero development by the placenta. Some other organs like brain (Baulieu 1998), and heart (Kayes-Wandover and White 2000) have also been identified as steroid-producing tissues, mainly for local needs. The steroid hormones are indispensable for mammalian life. They are made from cholesterol via complex biosynthetic pathways that are initiated by specialized, tissue-specific enzymes in mitochondria. These hormones include glucocorticoids (cortisol, corticosterone) and mineralocorticoids (aldosterone) produced in the adrenal cortex, estrogens (estradiol), progestins (progesterone) and androgens (testosterone, dihydrotestosterone) produced in the gonads, and calciferols (1,25-dihydroxy vitamin D [1,25OH2D]) produced in the kidneys (Miller and Auchus 2011). Cholesterol is the precursor for the synthesis of steroid hormones in mitochondria. Steroidogenesis begins with the metabolism of cholesterol to pregnenolone facilitated by P450scc. The rate of steroid formation depends on the rate of cholesterol transport from intracellular stores to the inner mitochondrial membrane and the loading of P450scc with cholesterol (Miller and Auchus 2011). Interference with one or more of these reactions leads to reduced steroid production.

This KE can be indirectly measured by: 1. Expression of the proteins involved in cholesterol transport by qPCR or Western blot. 3. Cholesterol transport to the mitochondrial inner membrane in intact cells: <ul> <li>Indirectly as pregnenolone formation by cells. The pregnenolone concentration is assayed by commercially available radioimmunoassays and reflects the amount of cholesterol transported to the mitochondrial inner membrane (Charman et al. 2010). </li> <li>Filipin staining is one of the most widely used tools for studying intracellular cholesterol distribution. The fluorescent detergent filipin binds selectively to cholesterol (and not to cholesterol esters) (Schroeder, Holland, and Bieber 1971). Filipin can be only used for the qualitative analysis of cholesterol distribution, since its fluorescence intensity is not necessarily linearly related to cholesterol content. </li> </ul> The cholesterol transport can be measured in vitro cultured Leydig cells. The methods for culturing Leydig cells can be found in the Database Service on Alternative Methods to animal experimentation (DB-ALM): Leydig Cell-enriched Cultures <a rel="nofollow" target="_blank" class="external autonumber" href="http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_met=232">[1]</a> Testicular Organ and Tissue Culture Systems <a rel="nofollow" target="_blank" class="external autonumber" href="http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_met=515">[2]</a>

The enzymes needed for cholesterol transport were found in amphioxus and are present in vertebrates (Albalat et al. 2011).

CL:0000174

CL steroid hormone secreting cell

High High High

Albalat, Ricard, Frédéric Brunet, Vincent Laudet, and Michael Schubert. 2011. “Evolution of Retinoid and Steroid Signaling: Vertebrate Diversification from an Amphioxus Perspective.” Genome Biology and Evolution 3: 985–1005. doi:10.1093/gbe/evr084. Baulieu, E E. 1998. “Neurosteroids: A Novel Function of the Brain.” Psychoneuroendocrinology 23 (8) (November): 963–87. Charman, Mark, Barry E Kennedy, Nolan Osborne, and Barbara Karten. 2010. “MLN64 Mediates Egress of Cholesterol from Endosomes to Mitochondria in the Absence of Functional Niemann-Pick Type C1 Protein.” Journal of Lipid Research 51 (5) (May): 1023–34. doi:10.1194/jlr.M002345. Kayes-Wandover, K M, and P C White. 2000. “Steroidogenic Enzyme Gene Expression in the Human Heart.” The Journal of Clinical Endocrinology and Metabolism 85 (7) (July): 2519–25. doi:10.1210/jcem.85.7.6663. Miller, Walter L, and Richard J Auchus. 2011. “The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders.” Endocrine Reviews 32 (1) (February): 81–151. doi:10.1210/er.2010-0013. Rone, Malena B, Jinjiang Fan, and Vassilios Papadopoulos. 2009. “Cholesterol Transport in Steroid Biosynthesis: Role of Protein-Protein Interactions and Implications in Disease States.” Biochimica et Biophysica Acta 1791 (7) (July): 646–58. doi:10.1016/j.bbalip.2009.03.001. Schroeder, F, J F Holland, and L L Bieber. 1971. “Fluorometric Evidence for the Binding of Cholesterol to the Filipin Complex.” The Journal of Antibiotics 24 (12) (December): 846–9. Steer, C. 1984. “Detection of Membrane Cholesterol by Filipin in Isolated Rat Liver Coated Vesicles Is Dependent upon Removal of the Clathrin Coat.” The Journal of Cell Biology 99 (1) (July 1): 315–319. doi:10.1083/jcb.99.1.315. AOPWiki 2016-11-29T18:41:24

2017-09-16T10:14:33

<upstream-id>bbccd06e-bb5a-4841-9c4e-08ed76bc3cb6</upstream-id> <downstream-id>20987ec4-5aa6-4abd-b536-1c139cd3a535</downstream-id>

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e981c9a8> AOPWiki 2016-11-29T18:41:34

2016-12-03T16:37:56

<upstream-id>a97f6563-3b5f-41d2-b203-025bec44ef4f</upstream-id> <downstream-id>b5f9ee93-568b-4b9a-bda1-56ff3816a64c</downstream-id> Impairment of testosterone production in testes directly impacts on testosterone levels.

Within the testes, steroid synthesis takes place within the mitochondria of Leydig cells. Testosterone production by Leydig cells is primarily under the control of LH. LH indirectly stimulates the transfer of cholesterol into the mitochondrial matrix to cholesterol side-chain cleavage cytochrome P450 (P450scc, CYP11A), which converts cholesterol to pregnenolone. Pregnenolone diffuses to the smooth endoplasmic reticulum where it is further metabolized to testosterone via the actions of 3β-hydroxysteroid dehydrogenase Δ5-Δ4-isomerase (3β-HSD), 17α-hydroxylase/C17-20 lyase (P450c17, CYP17), and 17β-hydroxysteroid dehydrogenase type III (17HSD3). For review see (Payne & Hales, 2013). Therefore, inhibition or impairment of the testosterone production directly impacts on the levels of testosterone.

There is evidence from experimental work that demonstrates a coordinated, dose-dependent reduction in the production of testosterone and consecutive reduction of testosterone levels in foetal testes and in serum, see Table 1. <table class="wikitable" id="Event439"> <tbody> <tr> <td>   </td> <td>   </td> <td>   </td> <td> KE: testosterone synthesis, reduction </td> <td> KE: testosterone, reduction </td> <td>   </td> <td>   </td> </tr> <tr> <td> Compound </td> <td> Species </td> <td> Effect level </td> <td>   </td> <td>   </td> <td> Details </td> <td> References </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL =300 mg/kg/day </td> <td> testicular testosterone production, reduction (ex vivo) </td> <td> testicular testosterone levels, reduction, no change plasma testosterone </td> <td> testosterone levels at GD 21 in male rat fetuses exposed to 0, 10, 30, 100, or 300 mg /kg bw/day from GD 7 to GD 21 testicular testosterone production ex vivo </td> <td> (Borch, Metzdorff, Vinggaard, Brokken, & Dalgaard, 2006) </td> </tr> <tr> <td> Phthalates (DBP) </td> <td> rat </td> <td> LOEL =50 mg/kg/day </td> <td>   </td> <td> testicular testosterone levels, reduction, </td> <td> Testicular testosterone was reduced >50 mg/kg/day </td> <td> (Shultz, 2001) </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=300 mg/kg/day </td> <td> fetal testicular testosterone production, reduction </td> <td>   </td> <td>   </td> <td> (Borch, Ladefoged, Hass, & Vinggaard, 2004)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=300 mg/kg/day </td> <td>   </td> <td> testicular testosterone levels, reduction, </td> <td>   </td> <td> (Borch et al., 2004)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=300 mg/kg/day </td> <td>   </td> <td> No change plasma testosterone </td> <td>   </td> <td> (Borch et al., 2004)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=100 mg/kg/day </td> <td>   </td> <td> Serum testosterone levels, reduction, </td> <td>   </td> <td> (Akingbemi, 2001)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=750 mg /kg /day </td> <td>   </td> <td> testicular testosterone levels, reduction, by 60 – 85% </td> <td>   </td> <td> (Parks, 2000) </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=750 mg /kg/day </td> <td>   </td> <td> testosterone levels, reduction, fetuses on GD 17 (71% lower than controls) and 18 (47% lower than controls) </td> <td>   </td> <td> (Parks, 2000)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=750mg/kg/day   </td> <td> ex vivo testosterone production, reduction by 50% </td> <td>   </td> <td>   </td> <td> (Wilson et al., 2004)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=234 mg/kg/day   </td> <td>   </td> <td> serum testosterone levels, reduction, </td> <td>   </td> <td> (Culty et al., 2008)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> LOEL=1250 mg/kg/day </td> <td> ex vivo foetal testicular production </td> <td>   </td> <td>   </td> <td> (Culty et al., 2008)   </td> </tr> <tr> <td> Phthalates (DEHP) </td> <td> rat </td> <td> ED50=444,2 mg/kg/day </td> <td> ex vivo foetal testicular production, reduction   </td> <td>     </td> <td>   </td> <td> (Hannas et al., 2012)   </td> </tr> <tr> <td> Phthalates (DHP) </td> <td> rat </td> <td> ED50=75.25 mg/kg/day   </td> <td> ex vivo foetal testicular production, reduction </td> <td>   </td> <td>   </td> <td> (Hannas et al., 2012)   </td> </tr> </tbody> </table> Table 1. Summary table for empirical support for this KER. ED50 - half maximal effective concentration, LOEL- lowest observed effect level, Dibutyl phthalate (DBP), Bis(2-ethylhexyl) phthalate (DEHP), Dihexyl Phthalate (DHP).

High High Moderate

Ses Table 1.

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e987d640> AOPWiki 2016-11-29T18:41:34

2016-12-02T10:18:05

<upstream-id>6e57c555-57cf-452c-a27d-bca3f9e6c8fb</upstream-id> <downstream-id>a97f6563-3b5f-41d2-b203-025bec44ef4f</downstream-id> Production of steroid hormones depends on the availability of cholesterol in the mitochondrial matrix. A decreased amount of cholesterol inside the mitochondria (e. g by decreased expression of enzymes that transport cholesterol like StAR or TSOP) means diminished substrate for hormone (testosterone) production in testes.

Steroid hormones play a critical role in sexual development, homeostasis, stress-responses, carbohydrate metabolism, tumor growth, and reproduction. These hormones are primarily produced in specialized steroidogenic tissues and are synthesized from a common precursor, cholesterol. Mitochondria are a key control point for the regulation of steroid hormone biosynthesis. The first and rate-limiting step in steroidogenesis is the transfer of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane, a process dependent on the action of StAR (Stocco, 2001) and the subsequent transport across the inner mitochondrial space into the steroidogenic pathway, which is executed by TSPO (Hauet et al., 2005). Testosterone production by Leydig cells is primarily under the control of luteinizing hormone (LH). Stimulation of the Leydig cells results in the activation of StAR transcription and translation, which facilitates the transfer of cholesterol into the mitochondrial matrix to cholesterol side-chain cleavage cytochrome P450 (P450scc, CYP11A), which converts cholesterol to pregnenolone. Pregnenolone diffuses to the smooth endoplasmic reticulum where it is further metabolized to testosterone via the actions of 3β-hydroxysteroid dehydrogenase Δ5-Δ4-isomerase (3β-HSD), 17α-hydroxylase/C17-20 lyase (P450c17, CYP17), and 17β-hydroxysteroid dehydrogenase type III (17HSD3). For review see (Payne & Hales, 2013). Decreased expression of genes that are responsible for cholesterol transport and steroidogenic enzyme activities in the Leydig cell leads to decreased testosterone production.

There is evidence from experimental work that demonstrates a coordinated reduction in the expression of key genes and proteins that are involved in cholesterol transport and steroidogenesis, together with a corresponding reduction in testosterone in testes. For details see Table 1. Foetal Leydig cells exhibit a high rate of lipid metabolism, which is required for both synthesizing and importing the testosterone precursor cholesterol. Upon exposure to some chemicals mRNA expression of genes in these pathways are profoundly reduced e.g. following 500mg/kg phthalate (DBP) exposure (Johnson, McDowell, Viereck, & Xia, 2011), (Thompson et al., 2005). Additionally, after phthalate exposure testis cholesterol and cholesterol-containing lipid droplets in foetal Leydig cells are also reduced (Barlow et al., 2003), (Johnson et al., 2011), (Lehmann, Phillips, Sar, Foster, & Gaido, 2004).   <table class="wikitable" id="Event438"> <tbody> <tr> <td> </td> <td> </td> <td> </td> <td> KE: Cholesterol transport, reduction </td> <td> KE: Testosterone production/levels, reduction </td> </tr> <tr> <td> Compound </td> <td> Species </td> <td> Effect level </td> <td> Translator protein (TSPO), decrease; Steroidogenic acute regulatory protein (StAR) decrease </td> <td> </td> </tr> <tr> <td> Phthalate (DBP) </td> <td> rat </td> <td> LOEL=500 mg/kg/day </td> <td> mRNA StAR decrease (by ~34%)(Barlow et al., 2003) </td> <td>   </td> </tr> <tr> <td> Phthalate (BBP, DPeP, DEHP, DHP, DiHeP, DCHP, DINP DHeP) </td> <td> rat </td> <td> </td> <td> </td> <td>   </td> </tr> <tr> <td> Phthalate (DBP, DEHP, BBP) </td> <td> Rat </td> <td> LOEL=750 mg/kg/day (GD14-18) </td> <td> </td> <td> testosterone production, reduction ex vivo fetal testes examined on GD18 (Wilson et al., 2004)   </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td>   </td> </tr> <tr> <td> Phthalate (DBP) </td> <td> rat </td> <td> LOEL=500 mg/kg/day </td> <td> reduced Leydig cell lipid content(Barlow et al., 2003) </td> <td>   </td> </tr> <tr> <td> Phthalate (DBP) </td> <td> rat </td> <td> LOEL=500 mg/kg/day GD 12 -20, examinations on GD20 </td> <td> total cholesterol levels, reduction </td> <td> intratesticular testosterone levels, reduction (by nearly 90%)(Johnson et al., 2011) </td> </tr> <tr> <td> Phthalate (DBP) </td> <td> rat </td> <td> LOEL=500 mg/kg/day (GD12-19) </td> <td> decrease uptake of cholesterol Leydig cell mitochondria gd 19 </td> <td> <pre> testosterone production, reduction ex vivo (Thompson, Ross, & Gaido, 2004) </pre> </td> </tr> <tr> <td> Phthalate (DEHP) </td> <td> mouse </td> <td> LOEL=1 g/kg/day </td> <td> reduced TSPO mRNA </td> <td> testosterone levels, reduction (Gazouli, 2002) </td> </tr> <tr> <td> Phthalate (DEHP) </td> <td> rat </td> <td> LOEL=300 mg/ kg/day   </td> <td> dose-dependently reduced StAR, TSOP mRNA (GD 21 testes), also on protein levels in Leydig cells (Borch, Metzdorff, Vinggaard, Brokken, & Dalgaard, 2006)   </td> <td>   </td> </tr> <tr> <td> Phthalate (DEHP) </td> <td> rat </td> <td> LOEL=300 mg/kg/day </td> <td>   </td> <td> testosterone production, reduction (ex vivo) testosterone levels, reduction (Borch et al., 2006), (Borch, Ladefoged, Hass, & Vinggaard, 2004) </td> </tr> <tr> <td> Phthalate (MEHP) </td> <td> mouse </td> <td> LOEC=100 μM </td> <td> <ul> <li> reduced TSPO mRNA levels by 50%, </li> <li> binding sites decreased by 50% </li> <li> no effect on receptor affinity </li> <li> inhibited the transfer or loading of cholesterol to the inner mitochondrial membrane P450scc. (Gazouli, 2002) </li> </ul> </td> <td>   </td> </tr> <tr> <td> Phthalate (MEHP) </td> <td> rat </td> <td> IC50 =100 μM </td> <td> <ul> <li> inhibited formation of progesterone (Gazouli, 2002) </li> </ul> </td> <td>   </td> </tr> <tr> <td> Phthalate (MEHP) </td> <td> rat </td> <td> LOEC=250 μM </td> <td> cholesterol transport, decrease (into the mitochondria of immature and adult Leydig cells) </td> <td> Testosterone, reduction by approximately 60%, in vitro ( immature and adult Leydig cells) (Svechnikov, Svechnikova, & Söder, 2008) </td> </tr> <tr> <td> Phthalate (DEHP) </td> <td> rat </td> <td> LOEL=750 mg/kg/day </td> <td>   </td> <td> testosterone production reduction, testosterone levels, reduction (testicular and whole-body T levels in fetal and neonatal male rats from GD 17 to PND 2. (Parks, 2000) </td> </tr> <tr> <td> Phthalate (MEHP) </td> <td> rat </td> <td> LOEC=1 μM </td> <td>   </td> <td> testosterone production, reduction dose-dependent (Chauvigné et al., 2011) </td> </tr> <tr> <td> Perfluorooctanoic acid (PFOA) </td> <td> mouse </td> <td> LOEL=5mg/kg/day </td> <td> </td> <td> plasma testosterone, reduction (by 37%)(Li et al., 2011) </td> </tr> <tr> <td> WY-14,643 </td> <td> mouse </td> <td> LOEC=50 mg/kg/day </td> <td> reduced TSPO mRNA </td> <td> Serum testosterone levels, reduction (Gazouli, 2002) </td> </tr> <tr> <td> WY-14,643 </td> <td> rat </td> <td> </td> <td>   </td> <td> No decrease of testosterone ( ex vivo), (Furr, Lambright, Wilson, Foster, & Gray, 2014) </td> </tr> <tr> <td> WY-14,643 </td> <td> mouse </td> <td> LOEC=100 μM </td> <td> Inhibited progesterone synthesis (Gazouli, 2002) </td> <td>   </td> </tr> <tr> <td> Bezafibrate </td> <td> mouse </td> <td> IC50=100 μM </td> <td> <ul> <li> a dose-dependent 10–95% inhibition of the progesterone synthesis at 24 or 72 h </li> <li> inhibited the transfer or loading of cholesterol to the inner mitochondrial membrane P450scc. At 100 μM </li> <li> binding sites of TSPO decreased IC50 of approximately 100 μM </li> <li> decrease TSPO levels by 60% at 100 μM (Gazouli, 2002) </li> </ul> </td> <td>   </td> </tr> <tr> <td> Bezafibrate </td> <td> rat </td> <td> IC50 = 30 μM </td> <td> inhibited formation of progesterone (Gazouli, 2002) </td> <td>   </td> </tr> <tr> <td> Bezafibrate </td> <td> rat </td> <td> IC50 ~10−4 μM </td> <td> </td> <td> testosterone production, reduction (Gazouli, 2002) </td> </tr> <tr> <td> Phthalate (DiBP) </td> <td> rat </td> <td> GD 19 -21 </td> <td> reduced StAR, (Boberg et al., 2008) </td> <td> testicular testosterone production and testicular testosterone levels, (Boberg et al., 2008) </td> </tr> </tbody> </table> Table 1. Summary table of empirical support for this KER. IC50 half maximal inhibitory concentration, LOEC-lowest effect concentration, LOEL- lowest observed effect level, Dibutyl phthalate (DBP), diisobutyl phthalate (DiBP), Bis(2-ethylhexyl) phthalate (DEHP), Dibutyl phthalate (DBP), Bezafibrate and WY-14,643 are PPARα ligands, n.a - not available

Thompson et al investigated time course effects of phthalate on steroidogenesis gene expression and testosterone concentration. The study showed diminished concentration testosterone concentration in the foetal testis by 50% within 1h of treatment with phthalate (DBP). Surprisingly, the diminution in testosterone concentration preceded any alteration in expression of genes in the steroidogenesis pathway. Star mRNA was significantly diminished 2 h after DBP exposure, but Cyp11a1, Cyp17a1, and Scarb1 did not show a significant decrease in expression until 6 h after DBP exposure (Thompson et al., 2005). In utero exposure of rats to PFOA 20 mg/kg did not cause any effect on fetal testosterone (Boberg et.al. 2008) although in mice (adult) the decrease level of testosterone was observed. Testosterone production may also be diminished due to reduction/inhibition of other genes involved in steroidogenesis (e.g. P450scc, Cyp17a1) (Thompson et al., 2004), (Boberg et al., 2008), (Chauvigné et al., 2009), (Chauvigné et al., 2011).

Moderate High Low

See Table 1.

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e98adfe8> AOPWiki 2016-11-29T18:41:34

2016-12-02T10:16:58

<upstream-id>b5f9ee93-568b-4b9a-bda1-56ff3816a64c</upstream-id> <downstream-id>0d427a7f-8f34-4a18-af88-8c16cd20d5dd</downstream-id>

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e98c1c28> AOPWiki 2016-11-29T18:41:34

2016-12-03T16:37:56

<upstream-id>0d427a7f-8f34-4a18-af88-8c16cd20d5dd</upstream-id> <downstream-id>bbccd06e-bb5a-4841-9c4e-08ed76bc3cb6</downstream-id>

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e98de378> AOPWiki 2016-11-29T18:41:34

2016-12-03T16:37:56

<upstream-id>20987ec4-5aa6-4abd-b536-1c139cd3a535</upstream-id> <downstream-id>15a5f0c6-3f3a-4860-af3c-95bff1d10201</downstream-id>

#<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42e98f4808> AOPWiki 2016-11-29T18:41:34

2016-12-03T16:37:56

PPARα activation leading to impaired fertility in adult male rodents

PPAR and reproductive toxicity

Evgeniia Kazymova

Malgorzata Nepelska, Sharon Munn, Brigitte Landesmann Systems Toxicology Unit, Institute for Health and Consumer Protection, Joint Research Centre, European Commission, Ispra, Varese, Italy

BY-SA

Under Development

1.21

1.0

Fibrates are ligands of PPARα (Staels et al. 1998). Phthalates MHEP (CAS 4376-20-9) directly binds in vitro to PPARα (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPARα (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPARα (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPARα (ToxCastTM Data). Notably, PPARα are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPARα [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)). Perfluorooctanoic Acid (PFOA) is known to activate PPARα (Vanden Heuvel et al. 2006). Organotin Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)

Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (≥ 1000 t.p.a.). Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) “reproductive toxicity” includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) “effects on fertility” includes adverse effects on sexual function and fertility; and c) “developmental toxicity” includes adverse effects on development of the offspring.

adjacent

Not Specified

Moderate adjacent

Not Specified

High adjacent

Not Specified

Moderate non-adjacent

Not Specified

Moderate non-adjacent

Not Specified

Moderate non-adjacent

Not Specified

Moderate

High Male

Moderate

Adult, reproductively mature

Moderate

Juvenile

High

AOPWiki 2016-11-29T18:41:16

2023-09-25T16:26:47